en · de · es · fr · pt
faq-desk.peptides6155.com › Data › Background And Research Status — Background and Details

Background And Research Status — Background and Details

By Editorial Desk · published 2025-07-22 · last reviewed 2025-09-11 · Data

LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Related pages on this site

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Further detail

== Use in imaging == Imaging is a useful tool in visualization of the radioligand after injection, with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) being the most common types of imaging. PET scans are often utilized after radioligand administration because of the ease of use, image accuracy, and non-invasive nature. While PET and SPECT scans function similarly when imaging radioligands, the main difference lies in the type of radiation used, with PET scans utilizing positrons and SPECT utilizing gamma rays. When comparing the two modalities, PET offers much better image quality and high diagnostic proficiency, however, the high cost and the short half-lives of the positron-emitting isotopes limit their overall availability. Alternatively, SPECT imaging is more dynamic because of the lower cost burden and longer half-lives of single-photon emitters. With advances in technology came hybrid imaging that can combine PET, SPECT, computed tomography (CT), and magnetic resonance imaging (MRI). Some hybrid imaging modalities include: PET–CT, SPECT/CT, and PET/MRI. Although combined imaging presents both cost and availability barriers, the technology is an extremely useful diagnostic tool. Often, the patient does not have to be moved for both imaging types to be completed, and the clinicians are provided with rich, multi-dimensional imaging.

Tandem Diabetes Care, Inc. is an American medical-device company that develops and markets insulin pumps, automated insulin delivery systems and diabetes-management software. Headquartered in San Diego, California, its principal pump platforms are the t:slim X2 and Tandem Mobi, both of which use the company's Control-IQ+ software with compatible continuous glucose monitors (CGMs). Tandem was founded in 2006 and introduced its first pump, the touchscreen t:slim, in 2012. The company became publicly traded on the Nasdaq in 2013. By the end of 2025 it reported an in-warranty user base of nearly 500,000 people in more than 25 countries and annual sales of $1.015 billion.

=== Antimicrobial scrubs === Antimicrobial scrubs can reduce the accumulation of odors and stains on scrubs, which in turn improves their longevity. These scrubs also come in a variety of colors and styles. As antimicrobial technology develops at a rapid pace, these scrubs are readily available, with more advanced versions hitting the market every year. These bacteria could then be spread to office desks, break rooms, computers, and other shared technology. This can lead to outbreaks and infections like methicillin-resistant staphylococcus aureus, treatments for which cost the healthcare industry $20 billion a year.

On June 22, 1941, Germany broke the Molotov–Ribbentrop Pact with Operation Barbarossa, the invasion of the Soviet Union through the territories that the two countries had previously divided. Stalin switched his cooperation from Hitler to Winston Churchill. Britain and the Soviets signed a formal alliance, but the US did not join until after the Attack on Pearl Harbor on December 7, 1941. Immediately, there was disagreement between Britain's ally Poland and the Soviet Union. The British and Poles strongly suspected that when Stalin was cooperating with Hitler, he ordered the execution of about 22,000 Polish officer POWs, at what was later to become known as the Katyn massacre. Still, the Soviets and the Western Allies were forced to cooperate, despite their tensions. The US shipped vast quantities of Lend-Lease material to the Soviets. Britain agreed a broader military and political alliance in 1942. During the war, both sides disagreed on military strategy, especially the question of the opening of a second front against Germany in Western Europe. As early as July 1941, Stalin asked Britain to invade northern France, but Britain was in no position to carry out such a request. Stalin had also requested that the Western Allies open a second front from the early months of the war—which finally occurred on D-Day, June 6, 1944. The US and Britain initially indicated that they would open the second front in 1942, and then in 1943, but it was postponed both times.

Some have pores underneath, others have spines, such as the hedgehog mushroom and other tooth fungi, and so on. "Mushroom" has been used for polypores, puffballs, jelly fungi, coral fungi, bracket fungi, stinkhorns, and cup fungi. Thus, the term is more one of common application to macroscopic fungal fruiting bodies than one having precise taxonomic meaning. Approximately 14,000 species of mushrooms are described.

Sources: en.wikipedia.org

Supporting material

== Mosaic Diagnostics, formerly Great Plains Laboratory == William Shaw's laboratory is known for performing nonstandard tests which have been used by alternative medicine practitioners to support discredited diagnoses. Great Plains Laboratory's urine mycotoxin test is not validated nor recommended for diagnosing any condition. In May 2020, early in the COVID-19 pandemic, Great Plains marketed unproven antibody tests.

== Gliding scandals == During the 2020 Women's World Gliding Championships at Lake Keepit, Australia, the home team captain Terry Cubley (Executive Officer of the GFA) was charged with unsporting behaviour for hacking the official tracking system to bypass the mandatory 15 minute delay and forward real time competitors' positions to his team, granting a tactical advantage. An investigation revealed that Matt Gage had been closely involved with the developers of the tracking system, and was aware of an undocumented back door that allowed the team captain (Terry Cubley) to bypass the 15 minute delay. This real-time information was relayed by the team captain over the radio to the Australian pilots. This was the first time in the sport's history that an entire team had been penalised for unsporting behaviour, with the Competition Director applying a penalty of 25 points per pilot per day. Controversially the pilots involved were spared disqualification only receiving a relatively trivial points reduction (compared to a competing pilot who was disqualified for infringing airspace earlier in the competition). Following a subsequent GFA investigation two of the Australian Team admitted to cheating and the GFA made a formal apology to the FAI and the wider gliding community. Terry Cubley was removed from his role as Vice President of the IGC, but chose to remain as Executive Officer of the GFA . The pilots involved chose to appeal against this decision, resulting in the longest and most comprehensive investigation in the FAIs history.

Asparagine peptide lyase are one of the seven groups in which proteases, also termed proteolytic enzymes, peptidases, or proteinases, are classified according to their catalytic residue. The catalytic mechanism of the asparagine peptide lyases involves an asparagine residue acting as nucleophile to perform a nucleophilic elimination reaction, rather than hydrolysis, to catalyse the breaking of a peptide bond. The existence of this seventh catalytic type of proteases, in which the peptide bond cleavage occurs by self-processing instead of hydrolysis, was demonstrated with the discovery of the crystal structure of the self-cleaving precursor of the Tsh autotransporter from E. coli.

=== Economics === Economists have modeled the circumstances under which slavery (and variants such as serfdom) appear and disappear. One theoretical model is that slavery becomes more desirable for landowners where land is abundant, but labour is scarce, such that rent is depressed and paid workers can demand high wages. If the opposite holds true, then it is more costly for landowners to guard the slaves than to employ paid workers who can demand only low wages because of the degree of competition. Thus, first slavery and then serfdom gradually decreased in Europe as the population grew. They were reintroduced in the Americas and in Russia as large areas of land with few inhabitants became available. Slavery is more common when the tasks are relatively simple and thus easy to supervise, such as large-scale monocrops such as sugarcane and cotton, in which output depended on economies of scale. This enables systems of labour, such as the gang system in the United States, to become prominent on large plantations where field hands toiled with factory-like precision. Then, each work gang was based on an internal division of labour that assigned every member of the gang to a task and made each worker's performance dependent on the actions of the others. The slaves chopped out the weeds that surrounded the cotton plants as well as excess sprouts. Plow gangs followed behind, stirring the soil near the plants and tossing it back around the plants. Thus, the gang system worked like an assembly line.

The bacteria might induce systemic resistance in the host plant, so it can better resist attack by a true pathogen. The bacteria might outcompete other (pathogenic) soil microbes, e.g., by siderophores, giving a competitive advantage at scavenging for iron. The bacteria might produce compounds antagonistic to other soil microbes, such as phenazine-type antibiotics or hydrogen cyanide. To be specific, certain P. fluorescens isolates produce the secondary metabolite 2,4-diacetylphloroglucinol (2,4-DAPG), the compound found to be responsible for antiphytopathogenic and biocontrol properties in these strains. The phl gene cluster encodes factors for 2,4-DAPG biosynthesis, regulation, export, and degradation. Eight genes, phlHGFACBDE, are annotated in this cluster and conserved organizationally in 2,4-DAPG-producing strains of P. fluorescens. Of these genes, phlD encodes a type III polyketide synthase, representing the key biosynthetic factor for 2,4-DAPG production. PhlD shows similarity to plant chalcone synthases and has been theorized to originate from horizontal gene transfer. Phylogenetic and genomic analysis, though, has revealed that the entire phl gene cluster is ancestral to P. fluorescens, many strains have lost the capacity, and it exists on different genomic regions among strains. Some experimental evidence supports all of these theories, in certain conditions; a good review of the topic is written by Haas and Defago. Several strains of P. fluorescens, such as Pf-5 and JL3985, have developed a natural resistance to ampicillin and streptomycin.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network